Jay Michael S Balagtas, MD
Pediatric Medicine · Palo Alto
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 1
- 1 carrier
- Office
- 1
Offices
1 location · Lpch Medical Group Div of Lucile · 332 clinicians in this group
Looking this up.
Plans that list them
1 plan · 1 carrier
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Balagtas’s office at (650) 498-7200 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
| Anthem Full Dual Advantage Aligned (HMO D-SNP) | Anthem Blue Cross | Listed | Oct 3, 2026 |
California Medical Board record
Licence A93450 · Current
Licensed to practise in California · since 2005 · expires 2027-05-31 · New York Medical College.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Medicaid work
$64,760 in 2024
Medicaid paid $64,760 for 327 billed services this clinician did in 2024, up to 31 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Long return visit (40+ min) | 310 | $62,241 |
| Return visit (30+ min) | 17 | $2,519 |
| 2024 | 327 | 2 | 31 | $64,760 |
| 2023 | 49 | 1 | 15 | $7,199 |
| 2022 | 14 | 1 | 14 | $1,599 |
See the largest Medicaid services in earlier years
2023
| Long return visit (40+ min) | 49 | $7,199 |
2022
| Long return visit (40+ min) | 14 | $1,599 |
Money from drug and device companies
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| JAZZ PHARMACEUTICALS INC. · A Phase 3 Randomized Trial for Patients With De Novo Aml Comparing Standard Therapy Including Gemtuzumab Ozogamicin Go To Cpx351 With Go · 2022 | Their institution | $83,250 |
| PFIZER INC. · An Open Label Phase 12 Clinical Study of Pd0332991 in Combination With Backbone Chemotherapy in Pediatric Patients With Rms and Ews · 2020 | Their institution | $12,540 |
| PFIZER INC. · Phase 1 Study To Evaluate the Safety and Pharmacokinetics of Palbociclib Ibranceregistered in Combination With Irinotecan and Temozolomide and in Combination With Topotecan and Cyclophosphamide in Pediatric Patients With Recurrent Or Refractory Solid Tumors · 2023 | Their institution | $11,189 |
| PFIZER INC. · Phase 1 Study To Evaluate the Safety and Pharmacokinetics of Palbociclib Ibranceregistered in Combination With Irinotecan and Temozolomide and in Combination With Topotecan and Cyclophosphamide in Pediatric Patients With Recurrent Or Refractory Solid Tumors · 2024 | Their institution | $9,240 |
| Incyte Corporation · A Pilot Study of the Immunological Effects of Neo Adjuvant Incb024360 in Patients With Epithelial Ovarian, Fallopian Tube Or Primary Citn-05 Peritoneal Carcinoma · 2020 | Their institution | $9,022 |
| PFIZER INC. · Phase 1 Study To Evaluate the Safety and Pharmacokinetics of Palbociclib Ibranceregistered in Combination With Irinotecan and Temozolomide and in Combination With Topotecan and Cyclophosphamide in Pediatric Patients With Recurrent Or Refractory Solid Tumors · 2022 | Their institution | $8,408 |
| PFIZER INC. · Phase 12 Study To Evaluate Palbociclib Ibrance in Combination With Irinotecan and Temozolomide Or in Combination With Topotecan and Cyclophosphamide in Pediatric Patients With Recurrent Or Refractory Solid Tumors · 2024 | Their institution | $7,000 |
| PFIZER INC. · Phase 1 Study To Evaluate the Safety and Pharmacokinetics of Palbociclib Ibranceregistered in Combination With Irinotecan and Temozolomide and in Combination With Topotecan and Cyclophosphamide in Pediatric Patients With Recurrent Or Refractory Solid Tumors · 2021 | Their institution | $6,025 |
| JAZZ PHARMACEUTICALS INC. · A Phase 3 Randomized Trial for Patients With De Novo Aml Comparing Standard Therapy Including Gemtuzumab Ozogamicin (Go) To Cpx-351 With Go, and the Addition of the Flt3 Inhibitor Gilteritinib for Patients With Flt3 Mutations · 2024 | Their institution | $6,000 |
| Incyte Corporation · A Phase 2 Study of the Jak1, Jak2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High Risk Crlf2 Rearranged and Or Jak Pathway Mutant Acute Lymphoblastic Leukemia · 2022 | Their institution | $5,218 |
| E.R. Squibb & Sons, L.L.C. · Coop/Isr Ph I Adolescent Melanoma · 2021 | Their institution | $5,000 |
| Incyte Corporation · A Phase 2 Study of the Jak1, Jak2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High Risk Crlf2 Rearranged and Or Jak Pathway Mutant Acute Lymphoblastic Leukemia · 2023 | Their institution | $5,000 |
| Novartis Pharmaceuticals Corporation · A Multi Center Open Label Non Controlled Phase II Study To Evaluate Efficacy and Safety of Oral Nilotinib in Pediatric Patients With Newly Diagnosed Ph Chronic Myelogenous Leukemia Cml in Chronic Phase Cp Or With Ph Cml in Cp Or Accelerated Phase Ap Resis · 2020 | Their institution | $2,800 |
| E.R. Squibb & Sons, L.L.C. · Phase II Pediatric Ph+ All - A Phase 2 Multi-Center, Historically-Controlled Study of Dasatinib Added To Standard Chemotherapy in Pediatric Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia · 2023 | Their institution | $2,000 |
| E.R. Squibb & Sons, L.L.C. · Coop/Isr Ph I Adolescent Melanoma · 2023 | Their institution | $2,000 |
| E.R. Squibb & Sons, L.L.C. · Phase Iia Nivo in Hl Pediatric (Nivo+Bv) - A Phase I/II Trial of Nivolumab Plus Ipilimumab in Children and Young Adults With Relapsed/Refractory Solid Tumors: A Children S Oncology Group Study Advl1412 · 2023 | Their institution | $1,500 |
| E.R. Squibb & Sons, L.L.C. · Phase Iia Nivo in Hl Pediatric (Nivo+Bv) · 2020 | Their institution | $1,500 |
| PFIZER INC. · Phase 1 Study To Evaluate the Safety and Pharmacokinetics of Palbociclib Ibranceregistered in Combination With Irinotecan and Temozolomide and in Combination With Topotecan and Cyclophosphamide in Pediatric Patients With Recurrent Or Refractory Solid Tumors · 2025 | Their institution | $1,320 |
| Novartis Pharmaceuticals Corporation · A Multi Center Open Label Non Controlled Phase II Study To Evaluate Efficacy and Safety of Oral Nilotinib in Pediatric Patients With Newly Diagnosed Ph Chronic Myelogenous Leukemia Cml in Chronic Phase Cp Or With Ph Cml in Cp Or Accelerated Phase Ap Resistant Or Intolerant To Either Imatinib Or Dasatinib · 2021 | Their institution | $1,000 |
| Incyte Corporation · A Phase 2 Study of the Jak1, Jak2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High Risk Crlf2 Rearranged and Or Jak Pathway Mutant Acute Lymphoblastic Leukemia · 2025 | Their institution | $1,000 |
| PFIZER INC. · Phase 12 Study To Evaluate Palbociclib Ibrance in Combination With Irinotecan and Temozolomide Or in Combination With Topotecan and Cyclophosphamide in Pediatric Patients With Recurrent Or Refractory Solid Tumors · 2025 | Their institution | $1,000 |
| Incyte Corporation · A Phase 2 Study of the Jak1, Jak2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High Risk Crlf2 Rearranged and Or Jak Pathway Mutant Acute Lymphoblastic Leukemia · 2024 | Their institution | $1,000 |
| Incyte Corporation · A Phase 2 Study of the Jak1, Jak2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High Risk Crlf2 Rearranged and Or Jak Pathway Mutant Acute Lymphoblastic Leukemia · 2019 | Their institution | $60 |
Professional record
- NPI
- 1942498928
- Licence
- CA A93450California A93450: Current · expires 2027-05-31
- Trained
- New York Medical College, 1998
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 2080P0207X (2080P0207X); Pediatrics (208000000X)
- Mailing address
- 1000 Welch Rd, Suite 300, Palo Alto, CA, 94304
- NPI first listed
- 2007-10-04
- NPI last updated
- 2024-04-16
- NPI record certified
- 2024-04-16
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 1000 Welch Rd, Palo Alto, CA, 94304